Tadalafil Response, CRP Linked

May 2013
Renal & Urology News;May2013, Vol. 12 Issue 5, p14
The article reports on the study conducted by researchers of Pusan National University School of Medicine in Pusan, Korea regarding the serum levels of C-reactive protein (CRP) may allow physicians to predict the response to tadalafil treatment for erectile dysfunction (ED) in male diabetics.


Related Articles

  • The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Gacci, Mauro; Salvi, Matteo; Sebastianelli, Arcangelo; Vignozzi, Linda; Corona, Giovanni; McVary, Kevin T.; Kaplan, Steven A.; Maggi, Mario; Carini, Marco; Oelke, Matthias // Research & Reports in Urology;Apr2013, Vol. 5, p99 

    A strong and independent association between lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and erectile dysfunction (ED) has been widely evidenced in several clinical epidemiologic studies. Preclinical animal models have provided a great deal of information...

  • Once-daily Tadalafil for ED: Efficacy and Safety.  // Neurology Alert;Sep2013 Clinical Briefs, p17 

    The article discusses research on the efficacy and safety of tadalafil in restoring sexual function in men, which was conducted by A.D. Seftel and colleagues and published in the 2013 issue of the "International Journal of Impotence Research."

  • Tadalafil abuse.  // Reactions Weekly;Aug2014, Vol. 1512 Issue 1, p34 

    The article presents a case study of a 43-year-old man who was admitted to hospital for acute ischaemia after intra-arterial injection of tadalafil gel into artery of left wrist.

  • Pharmacologic Therapy for Erectile Dysfunction and its Interaction With the Cardiovascular System. Ioakeimidis, Nikolaos; Kostis, John B. // Journal of Cardiovascular Pharmacology & Therapeutics;Jan2014, Vol. 19 Issue 1, p53 

    Phosphodiesterase (PDE) enzymes are widely distributed throughout the body, having numerous effects and functions. The PDE type 5 (PDE5) inhibitors are widely used to treat erectile dysfunction (ED). Recent, intense preclinical and clinical research with PDE5 inhibitors has shed light on new...

  • Once-daily Tadalafil for ED: Efficacy and Safety.  // OB/GYN Clinical Alert;Sep2013 Clincal Briefs, p17 

    The article focuses on a study related to the safety and efficacy of once daily tadalafil (TAD-QD) in doses ranging from 2.5-10.0 miligram per day and also highlights that TAD-QD has more than doubled the rates of successful intercourse.

  • Tadalafil.  // Reactions Weekly;10/13/2012, Issue 1423, p46 

    The article describes the case of a 57-year-old man who developed retinal toxicity while undergoing tadalafil therapy.

  • Bosentan/epoprostenol/tadalafil.  // Reactions Weekly;2/13/2016, Vol. 1588 Issue 1, p55 

    The article presents a case study report of 44-year old man having pulmonary arterial hypertension associated with Sjogren's syndrome developed nasal congestion and lower extremity oedema on treatment with bosentan, epoprostenol and tadalafil.

  • Erectile dysfunction drug approved to treat BPH symptoms.  // Mayo Clinic Health Letter;Apr2012, Vol. 30 Issue 4, p4 

    The article reports that the U.S. Food and Drug Administration has approved tadalafil (Cialis) as a drug for the treatment of urinary symptoms of benign prostatic hyperplasia (BHP).

  • Once-daily Tadalafil for ED: Efficacy and Safety.  // Clinical Oncology Alert;Sep2013 Clincal Briefs, p17 

    The article discusses the study of A. D. Seftel and colleagues regarding the efficacy and safety of daily doses of tadalafil (TAD-QD) in men who suffer from mild-moderate erectile dysfunction (ED).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics